Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD

38.65  +0.72 (+1.9%)

After market: 38.65 0 (0%)

Fundamental Rating

6

Taking everything into account, SUPN scores 6 out of 10 in our fundamental rating. SUPN was compared to 195 industry peers in the Pharmaceuticals industry. SUPN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on SUPN. These ratings could make SUPN a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year SUPN was profitable.
In the past year SUPN had a positive cash flow from operations.
Each year in the past 5 years SUPN has been profitable.
In the past 5 years SUPN always reported a positive cash flow from operatings.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

1.2 Ratios

SUPN has a Return On Assets of 4.45%. This is amongst the best in the industry. SUPN outperforms 87.63% of its industry peers.
The Return On Equity of SUPN (5.93%) is better than 87.10% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.97%, SUPN belongs to the top of the industry, outperforming 82.80% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 43.82%.
The 3 year average ROIC (3.33%) for SUPN is below the current ROIC(5.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.45%
ROE 5.93%
ROIC 5.97%
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40

1.3 Margins

The Profit Margin of SUPN (9.16%) is better than 87.10% of its industry peers.
In the last couple of years the Profit Margin of SUPN has declined.
Looking at the Operating Margin, with a value of 12.19%, SUPN belongs to the top of the industry, outperforming 83.87% of the companies in the same industry.
SUPN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 89.04%, SUPN belongs to the top of the industry, outperforming 91.94% of the companies in the same industry.
SUPN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 12.19%
PM (TTM) 9.16%
GM 89.04%
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 5.30 indicates that SUPN is not in any danger for bankruptcy at the moment.
SUPN has a Altman-Z score of 5.30. This is amongst the best in the industry. SUPN outperforms 80.65% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.3
ROIC/WACC0.63
WACC9.5%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.20 indicates that SUPN has no problem at all paying its short term obligations.
The Current ratio of SUPN (2.20) is comparable to the rest of the industry.
A Quick Ratio of 1.98 indicates that SUPN should not have too much problems paying its short term obligations.
SUPN has a Quick ratio (1.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.98
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 134.04%, which is quite impressive.
The Earnings Per Share has been decreasing by -7.43% on average over the past years.
The Revenue has been growing slightly by 6.78% in the past year.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.24% yearly.
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS Q2Q%187.5%
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Sales Q2Q%14.17%

3.2 Future

The Earnings Per Share is expected to grow by 24.16% on average over the next years. This is a very strong growth
SUPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.81% yearly.
EPS Next Y108.13%
EPS Next 2Y17.45%
EPS Next 3Y19.35%
EPS Next 5Y24.16%
Revenue Next Year7.46%
Revenue Next 2Y1.98%
Revenue Next 3Y4.64%
Revenue Next 5Y6.81%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 17.57, SUPN is valued on the expensive side.
86.02% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
SUPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.39.
SUPN is valuated rather expensively with a Price/Forward Earnings ratio of 20.01.
Based on the Price/Forward Earnings ratio, SUPN is valued cheaply inside the industry as 81.18% of the companies are valued more expensively.
SUPN is valuated cheaply when we compare the Price/Forward Earnings ratio to 94.38, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.57
Fwd PE 20.01
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaply inside the industry as 89.78% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaper than 90.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.4
EV/EBITDA 8.11
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of SUPN may justify a higher PE ratio.
SUPN's earnings are expected to grow with 19.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y17.45%
EPS Next 3Y19.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (2/11/2025, 6:54:00 PM)

After market: 38.65 0 (0%)

38.65

+0.72 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners110.07%
Inst Owner Change-15.18%
Ins Owners3.91%
Ins Owner Change1.05%
Market Cap2.13B
Analysts80
Price Target44.88 (16.12%)
Short Float %11.47%
Short Ratio17.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.54%
Min EPS beat(2)-9.5%
Max EPS beat(2)52.59%
EPS beat(4)2
Avg EPS beat(4)17.11%
Min EPS beat(4)-32.33%
Max EPS beat(4)57.69%
EPS beat(8)4
Avg EPS beat(8)20.2%
EPS beat(12)5
Avg EPS beat(12)0.79%
EPS beat(16)8
Avg EPS beat(16)9%
Revenue beat(2)2
Avg Revenue beat(2)10.18%
Min Revenue beat(2)9.5%
Max Revenue beat(2)10.86%
Revenue beat(4)3
Avg Revenue beat(4)5.21%
Min Revenue beat(4)-3.43%
Max Revenue beat(4)10.86%
Revenue beat(8)5
Avg Revenue beat(8)2.24%
Revenue beat(12)8
Avg Revenue beat(12)1.82%
Revenue beat(16)10
Avg Revenue beat(16)1.41%
PT rev (1m)12.1%
PT rev (3m)12.1%
EPS NQ rev (1m)4%
EPS NQ rev (3m)12.23%
EPS NY rev (1m)0%
EPS NY rev (3m)41.42%
Revenue NQ rev (1m)0.59%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)3.78%
Valuation
Industry RankSector Rank
PE 17.57
Fwd PE 20.01
P/S 3.27
P/FCF 12.4
P/OCF 12.37
P/B 2.12
P/tB 6.1
EV/EBITDA 8.11
EPS(TTM)2.2
EY5.69%
EPS(NY)1.93
Fwd EY5%
FCF(TTM)3.12
FCFY8.06%
OCF(TTM)3.12
OCFY8.08%
SpS11.81
BVpS18.24
TBVpS6.34
PEG (NY)0.16
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.45%
ROE 5.93%
ROCE 7.56%
ROIC 5.97%
ROICexc 9.69%
ROICexgc N/A
OM 12.19%
PM (TTM) 9.16%
GM 89.04%
FCFM 26.39%
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
ROICexc(3y)4.56%
ROICexc(5y)9.78%
ROICexgc(3y)55.58%
ROICexgc(5y)44.39%
ROCE(3y)4.65%
ROCE(5y)8.65%
ROICexcg growth 3Y27.21%
ROICexcg growth 5Y23.08%
ROICexc growth 3Y-54.6%
ROICexc growth 5Y-42.12%
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.56%
Cap/Sales 0.07%
Interest Coverage 1727.26
Cash Conversion 106.05%
Profit Quality 288.16%
Current Ratio 2.2
Quick Ratio 1.98
Altman-Z 5.3
F-Score8
WACC9.5%
ROIC/WACC0.63
Cap/Depr(3y)2.42%
Cap/Depr(5y)13.27%
Cap/Sales(3y)0.17%
Cap/Sales(5y)0.37%
Profit Quality(3y)2941.76%
Profit Quality(5y)1811.14%
High Growth Momentum
Growth
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS Q2Q%187.5%
EPS Next Y108.13%
EPS Next 2Y17.45%
EPS Next 3Y19.35%
EPS Next 5Y24.16%
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Sales Q2Q%14.17%
Revenue Next Year7.46%
Revenue Next 2Y1.98%
Revenue Next 3Y4.64%
Revenue Next 5Y6.81%
EBIT growth 1Y164.85%
EBIT growth 3Y-56.57%
EBIT growth 5Y-36.49%
EBIT Next Year16.63%
EBIT Next 3Y12.89%
EBIT Next 5Y16.38%
FCF growth 1Y25.05%
FCF growth 3Y-6.45%
FCF growth 5Y-2.92%
OCF growth 1Y25.02%
OCF growth 3Y-7.07%
OCF growth 5Y-2.95%